To functionally test this, we blocked IFNγ production using IL-18BP (36) and type I IFN signaling using the anti-IFN α receptor 1 (IFNAR1) antibody anifrolumab, which is in clinical trials to treat systemic lupus erythematosus (34). The gene discussed is IL18BP; the disease is systemic lupus erythematosus.